Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.

Moysidou GS, Marotte H, Kossi S, Tubach F, Hajage D, Fautrel B

Open source

DOI
10.55563/clinexprheumatol/eonoj3
Published
2023 Sep
Container
Clinical and experimental rheumatology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.55563/clinexprheumatol/eonoj3,
  title = {Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.},
  author = {Moysidou GS and Marotte H and Kossi S and Tubach F and Hajage D and Fautrel B},
  year = {2023},
  journal = {Clinical and experimental rheumatology},
  doi = {10.55563/clinexprheumatol/eonoj3},
  url = {https://doi.org/10.55563/clinexprheumatol/eonoj3}
}

RIS

TY  - JOUR
TI  - Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
AU  - Moysidou GS
AU  - Marotte H
AU  - Kossi S
AU  - Tubach F
AU  - Hajage D
AU  - Fautrel B
PY  - 2023
JO  - Clinical and experimental rheumatology
DO  - 10.55563/clinexprheumatol/eonoj3
UR  - https://doi.org/10.55563/clinexprheumatol/eonoj3
ER  - 

APA

GS, M., H, M., S, K., F, T., D, H., & B, F. (2023). Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.. Clinical and experimental rheumatology. https://doi.org/10.55563/clinexprheumatol/eonoj3

Source records